Tienchi and Reduced C-Reactive Protein Levels

• To study the mechanism of panax notoginseng in the treatment of aspirin resistance in the secondary prevention of stroke based on TLR4/MyD88/NF-κB signaling pathway: A study protocol.

  • 2022-12-16
  • RCT · n = 106
  • Medicine 101(50)
  • • Hui Wang
    • Jie Yuan
    • Ying Wang
    • Jie Chen

  • PubMed: 36550905
  • DOI: 10.1097/md.0000000000031919

  8 Insights on

  • Reduced C-Reactive Protein Levels

  • High evidence
  • Large Human Trial
  • Clinical

  Patients will be measured with the platelet aggregation rate and serum TLR4, MyD88, NF-κB, COX-2, IL-6, CRP, TXB2 level for clinical efficacy and mechanisms at baseline and the 14th, 30th day of treatment.

  Effect

  Neutral

  Effect size

  Small

  Significant

  No